Annual Revenue
$560.23 M
+$125.98 M+29.01%
December 1, 2024
Summary
- As of March 7, 2025, RARE annual revenue is $560.23 million, with the most recent change of +$125.98 million (+29.01%) on December 1, 2024.
- During the last 3 years, RARE annual revenue has risen by +$208.82 million (+59.43%).
- RARE annual revenue is now at all-time high.
Performance
RARE Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
$164.88 M
+$25.38 M+18.20%
December 1, 2024
Summary
- As of March 7, 2025, RARE quarterly revenue is $164.88 million, with the most recent change of +$25.38 million (+18.20%) on December 1, 2024.
- Over the past year, RARE quarterly revenue has increased by +$37.48 million (+29.42%).
- RARE quarterly revenue is now at all-time high.
Performance
RARE Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM Revenue
$560.23 M
+$37.48 M+7.17%
December 1, 2024
Summary
- As of March 7, 2025, RARE TTM revenue is $560.23 million, with the most recent change of +$37.48 million (+7.17%) on December 1, 2024.
- Over the past year, RARE TTM revenue has increased by +$125.98 million (+29.01%).
- RARE TTM revenue is now at all-time high.
Performance
RARE TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
RARE Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +29.0% | +29.4% | +29.0% |
| 3 y3 years | +59.4% | +97.7% | +59.4% |
| 5 y5 years | +440.2% | +363.2% | +440.2% |
RARE Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +59.4% | at high | +106.3% | at high | +68.8% |
| 5 y | 5-year | at high | +440.2% | at high | +363.2% | at high | +440.2% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% | at high | >+9999.0% |
Ultragenyx Pharmaceutical Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $560.23 M(+29.0%) | $164.88 M(+18.2%) | $560.23 M(+7.2%) |
| Sep 2024 | - | $139.49 M(-5.1%) | $522.75 M(+8.6%) |
| Jun 2024 | - | $147.03 M(+35.1%) | $481.30 M(+8.7%) |
| Mar 2024 | - | $108.83 M(-14.6%) | $442.59 M(+1.9%) |
| Dec 2023 | $434.25 M(+19.5%) | $127.39 M(+29.9%) | $434.25 M(+5.9%) |
| Sep 2023 | - | $98.05 M(-9.5%) | $410.20 M(+1.8%) |
| Jun 2023 | - | $108.31 M(+7.8%) | $402.86 M(+4.9%) |
| Mar 2023 | - | $100.50 M(-2.8%) | $383.89 M(+5.7%) |
| Dec 2022 | $363.33 M(+3.4%) | $103.35 M(+13.9%) | $363.33 M(+5.8%) |
| Sep 2022 | - | $90.70 M(+1.5%) | $343.37 M(+2.7%) |
| Jun 2022 | - | $89.34 M(+11.8%) | $334.31 M(+0.7%) |
| Mar 2022 | - | $79.94 M(-4.1%) | $331.95 M(-5.5%) |
| Dec 2021 | $351.41 M(+29.7%) | $83.39 M(+2.1%) | $351.41 M(-2.3%) |
| Sep 2021 | - | $81.65 M(-6.1%) | $359.56 M(+0.0%) |
| Jun 2021 | - | $86.97 M(-12.5%) | $359.38 M(+7.6%) |
| Mar 2021 | - | $99.39 M(+8.6%) | $334.12 M(+23.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2020 | $271.03 M(+161.3%) | $91.54 M(+12.4%) | $271.03 M(+26.0%) |
| Sep 2020 | - | $81.47 M(+32.0%) | $215.08 M(+34.9%) |
| Jun 2020 | - | $61.71 M(+70.0%) | $159.41 M(+30.8%) |
| Mar 2020 | - | $36.31 M(+2.0%) | $121.85 M(+17.5%) |
| Dec 2019 | $103.71 M(+101.4%) | $35.59 M(+38.0%) | $103.71 M(+22.9%) |
| Sep 2019 | - | $25.80 M(+6.8%) | $84.38 M(+20.0%) |
| Jun 2019 | - | $24.15 M(+32.9%) | $70.34 M(+19.2%) |
| Mar 2019 | - | $18.17 M(+11.8%) | $58.99 M(+14.6%) |
| Dec 2018 | $51.49 M(+1871.5%) | $16.26 M(+38.2%) | $51.49 M(+36.8%) |
| Sep 2018 | - | $11.76 M(-8.1%) | $37.65 M(+44.3%) |
| Jun 2018 | - | $12.79 M(+19.8%) | $26.08 M(+96.3%) |
| Mar 2018 | - | $10.68 M(+342.3%) | $13.29 M(+408.8%) |
| Dec 2017 | $2.61 M(+1863.9%) | $2.41 M(+1119.2%) | $2.61 M(+1186.7%) |
| Sep 2017 | - | $198.00 K(+3860.0%) | $203.00 K(+52.6%) |
| Dec 2016 | $133.00 K | $5000.00(-95.5%) | $133.00 K(+3.9%) |
| Sep 2016 | - | $111.00 K(+552.9%) | $128.00 K(+652.9%) |
| Jun 2016 | - | $17.00 K | $17.00 K |
FAQ
- What is Ultragenyx Pharmaceutical annual revenue?
- What is the all time high annual revenue for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual revenue year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly revenue?
- What is the all time high quarterly revenue for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly revenue year-on-year change?
- What is Ultragenyx Pharmaceutical TTM revenue?
- What is the all time high TTM revenue for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical TTM revenue year-on-year change?
What is Ultragenyx Pharmaceutical annual revenue?
The current annual revenue of RARE is $560.23 M
What is the all time high annual revenue for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual revenue is $560.23 M
What is Ultragenyx Pharmaceutical annual revenue year-on-year change?
Over the past year, RARE annual revenue has changed by +$125.98 M (+29.01%)
What is Ultragenyx Pharmaceutical quarterly revenue?
The current quarterly revenue of RARE is $164.88 M
What is the all time high quarterly revenue for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly revenue is $164.88 M
What is Ultragenyx Pharmaceutical quarterly revenue year-on-year change?
Over the past year, RARE quarterly revenue has changed by +$37.48 M (+29.42%)
What is Ultragenyx Pharmaceutical TTM revenue?
The current TTM revenue of RARE is $560.23 M
What is the all time high TTM revenue for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high TTM revenue is $560.23 M
What is Ultragenyx Pharmaceutical TTM revenue year-on-year change?
Over the past year, RARE TTM revenue has changed by +$125.98 M (+29.01%)